International Journal of Colorectal Disease

, Volume 25, Issue 3, pp 401–404

Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery

Authors

    • MGH Crohn’s & Colitis CenterHarvard Medical School
    • Department of SurgeryMassachusetts General Hospital
  • Hiroko Kunitake
    • MGH Crohn’s & Colitis CenterHarvard Medical School
    • Department of SurgeryMassachusetts General Hospital
  • Paul Shellito
    • MGH Crohn’s & Colitis CenterHarvard Medical School
    • Department of SurgeryMassachusetts General Hospital
  • Richard Hodin
    • MGH Crohn’s & Colitis CenterHarvard Medical School
    • Department of SurgeryMassachusetts General Hospital
Original Article

DOI: 10.1007/s00384-009-0800-5

Cite this article as:
Bordeianou, L., Kunitake, H., Shellito, P. et al. Int J Colorectal Dis (2010) 25: 401. doi:10.1007/s00384-009-0800-5

Abstract

Introduction

A recent study has raised concerns that infliximab treatment, by postpoing surgery for ulcerative and indeterminate colitis patients, may result in a greater need for high-risk emergent or multistep surgical procedures (subtotal colectomies). Our aim was to assess whether infliximab exposure affects rates of subotal colectomy in a large cohort of patients.

Methods

We evaluated 171 consecutive patients with ulcerative or indeterminate colitis who had a total proctocolectomy or a subtotal colectomy between 1993 and 2006 for symptoms of unremitting disease. Forty-four patients (25.7%) received infliximab prior to surgery. We compared the surgical procedures employed on these 44 patients to the surgical procedures employed on the 127 non-infliximab patients, using Fisher’s exact or Student’s t test.

Results

Infliximab exposure did not appear to affect the rate of emergent surgery (4.5% vs 4.4%, p = 0.98), rate of subtotal colectomy (19.2% vs. 18.0%, p = 0.99), or rate of ileoanal J pouch reconstruction (53.8% vs. 62%, p = 0.98). Nor did it affect intraoperative findings of perforation, toxic megacolon, and active disease. The infliximab and non-infliximab cohorts were similar in age, Charlson Comorbidity Index, concomitant steroid use, and albumin levels, although infliximab patients had higher rates of concomitant exposure to 6-mercaptopurine (34.1% vs 16.6%, p = 0.02) and azathioprine (40.9% vs 22.6%, p = 0.02).

Conclusion

Infliximab does not appear to increase rates of emergent surgery or multistep procedures in patients undergoing treatment for ulcerative or indeterminative colitis at our institution.

Keywords

Infliximab Subtotal colectomy Surgical complications Ulcerative colitis

Copyright information

© Springer-Verlag 2009